Amygdala Neurosciences Selects ANS-858 for Clinical Development as a Novel ALDH2 Inhibitor for Substance Use Disorder ...Middle East

The discovery and preclinical efficacy of ANS-858, a proprietary, selective, reversible, orally bioavailable ALDH2 inhibitor will be presented at 48th Annual Scientific Meeting of the Research Society on Alcohol. SAN FRANCISCO, April 2, 2025 /PRNewswire/ -- Amygdala Neurosciences, Inc., a...

Hence then, the article about amygdala neurosciences selects ans 858 for clinical development as a novel aldh2 inhibitor for substance use disorder was published today ( Thursday 03/04/2025 - 12:49 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Amygdala Neurosciences Selects ANS-858 for Clinical Development as a Novel ALDH2 Inhibitor for Substance Use Disorder )

Also on site :

• XPENG-Peking University Collaborative Research Accepted by AAAI 2026: Introducing a Novel Visual Token Pruning Framework for Autonomous Driving
• John Legend Celebrates 47th Birthday With Family Slime Outing in New York
• Kurtenbach: These unbelievable 49ers might just be a team of destiny